Phathom Pharmaceuticals Inc

PHAT

Healthcare|Biotechnology|USA

$12.61

+0.45 (+3.70%)

Clinical Trials (16)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT07224048 Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2	H. Pylori Infection, Gastric Cancer	P4	Active	75	RCT, Open-label	PYTEST® 14C-Urea Capsule Breath Test (at Home), PYTEST® 14C-Urea Capsule Breath Test (Standard Retesting In-Person)
NCT07224035 Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1	H Pylori Infection, H Pylori Gastritis	P4	Active	500	Open-label	PYTEST® 14C-Urea Breath Test, VOQUEZNA® Triple Pak®
NCT06851559 A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks	Eosinophilic Esophagitis	P2	Active	95	RCT, Double-blind	Vonoprazan, Placebo
NCT06660342 A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring	Erosive Esophagitis, Heartburn		Recruiting	728	—	Vonoprazan
NCT04167670 Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection	Helicobacter Pylori Infection	P3	Completed	1,046	RCT, Double-blind	Vonoprazan, Amoxicillin, Clarithromycin, Lansoprazole
NCT04124926 Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis	Erosive Esophagitis	P3	Completed	1,027	RCT, Double-blind	Vonoprazan, Lansoprazole
NCT05195528 A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)	Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn	P3	Completed	776	RCT, Double-blind	Vonoprazan, Placebo
NCT04799158 A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease	Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn	P2	Completed	458	RCT, Double-blind	Vonoprazan, Placebo
NCT06831344 A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants	Healthy Volunteers	P1	Completed	25	RCT, Open-label	Vonoprazan ODT-1 or ODT-2 without Water, Vonoprazan ODT-1 or ODT-2 with Water, Vonoprazan (Reference)
NCT04558216 Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants	Healthy Participants	P1	Withdrawn	—	Open-label	Vonoprazan, Rifampin
NCT06391177 A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily	Erosive Esophagitis, Heartburn	P1	Completed	15	Open-label	Vonoprazan
NCT04545944 Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants	Healthy Volunteers	P1	Completed	20	Open-label	Vonoprazan, Midazolam
NCT06106022 A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease	Gastroesophageal Reflux Disease	P1	Completed	22	RCT, Open-label	Vonoprazan
NCT05343364 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease	Gastroesophageal Reflux	P1	Completed	24	RCT, Open-label	Vonoprazan
NCT05366738 A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants	Healthy Volunteers	P1	Completed	27	RCT, Open-label	Vonoprazan, Vonoprazan
NCT04729101 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants	Healthy Participants	P1	Completed	44	RCT, Open-label	Vonoprazan, Lansoprazole